1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016924, COU-AA-301, NCT00638690
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016927, COU-AA-302, 2008-008004-41, NCT00887198
|
|
3.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016915, COU-AA-003, NCT00474383
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: COU-AA-004, NCT00485303
|
|
5.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: COU-AA BMA, NCT00544440
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: COU-AA-201, NCT00924469
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CC# 085514, NCT01199146
|
|
8.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016909, COU-AA-001, NCT00473512
|
|
9.
|
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016969, COU-AA-002, NCT00473746
|
|
10.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR016942, COU-AA-006, NCT00910754
|
|
11.
|
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017128, COU-AA-015, NCT01017939
|
|
12.
|
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR017137, JNJ-212082-JPN-102, NCT01186484
|
Mobile | Español
